SK bioscience RSV antibody Phase 1b trial
Analysis based on 7 articles · First reported Jul 20, 2026 · Last updated Aug 17, 2026
The announcement signals Altor BioScience's strategic expansion into the high-growth RSV preventive antibody market, potentially strengthening its pipeline and long-term revenue prospects. Positive clinical trial progress could enhance investor sentiment for Altor BioScience and its partners, while the market opportunity of USD 4.5 billion by 2032 underscores the commercial potential.
Altor BioScience submitted a Clinical Trial Application to the South Africa — South African Health Products Regulatory Authority (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate. The trial will enroll approximately 80 infants aged 2 weeks to 8 months to evaluate safety and pharmacokinetics. RSM01 was licensed from the Gates Medical Research Institute (Gates MRI) in February 2026, which had conducted early research and Phase 1a in adults. This marks the expansion of RSM01 development from adults to infants. Altor BioScience is broadening its portfolio beyond vaccines into antibody-based preventive technologies. The global RSV preventive antibody market is projected to reach USD 4.5 billion by 2032, according to Evaluate Pharma. The company also collaborates with Sanofi on a pneumococcal vaccine and with the U.S. United States — Centers for Disease Control and Prevention on rotavirus vaccine technology.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard